Swiss Biotech Day: Molecular Partners' CEO and Swiss Biotech Association president Patrick Amstutz shares his take on biotech and previews what to expect from his U.S. listed company in 2025

He describes the clinical multi-specific T-cell engager program that will have data this year, and highlights the idea behind a next-generation logic-gating platform. Plus, entering the clinic with a DLL3 radio-DARPin and choosing mesothelin as a second target.